Upcoming loss-of-exclusivity events for branded drugs, ranked by Medicare Part D spending.
Orange Book data: Jul 1, 2026 · Medicare spending: 2024 data (CMS 18–24 month lag)
$5.8B
Revenue at risk (12mo) — 2024 data
15
Expiring in 90 days
59
Expiring in 12 months
557
With Para IV filings
Highest Revenue at Risk
| Drug | Patents | LOE Date | Medicare Spend (2024) ↓ |
|---|---|---|---|
| REVLIMIDN021880 | 2 | Mar 8, 2028(1.6yr) | $6.8B |
| JANUVIAN021995 | 1 | May 24, 2027(10mo) | $3.8B |
| PROMACTAN022291 | 6 | Feb 1, 2028(1.5yr) | $672M |
| SPRYCELN021986 | 1 | Sep 28, 2026(2mo) | $518M |
| STIOLTO RESPIMATN206756 | 1 | Jan 19, 2027(6mo) | $449M |
| INCRUSE ELLIPTAN205382 | 1 | Dec 18, 2027(1.4yr) | $376M |
| JANUMET XRN202270 | 1 | May 24, 2027(10mo) | $358M |
| VYNDAQELN211996 | 2 | Dec 19, 2026(5mo) | $304M |
| XELJANZN203214 | 1 | Feb 21, 2028(1.6yr) | $274M |
| NUEDEXTAN021879 | 1 | Aug 13, 2026(1mo) | $173M |
| DIFICIDN201699 | 4 | Jan 31, 2028(1.5yr) | $154M |
| PRISTIQN021992 | 1 | Jul 5, 2027(12mo) | $67M |
| AMITIZAN021908 | 3 | Oct 25, 2027(1.3yr) | $59M |
| NOURIANZN022075 | 2 | Jan 28, 2028(1.5yr) | $51M |
| CORLANORN206143 | 4 | Jun 12, 2027(11mo) | $40M |
| NAYZILAMN211321 | 4 | Jan 18, 2028(1.5yr) | $37M |
| EDARBIN200796 | 1 | Mar 26, 2028(1.7yr) | $37M |
| ALVESCON021658 | 1 | Feb 1, 2028(1.5yr) | $35M |
| AZILECTN021641 | 2 | Aug 27, 2027(1.1yr) | $30M |
| OXTELLAR XRN202810 | 11 | Apr 13, 2027(9mo) | $28M |
| SAPHRISN022117 | 2 | Oct 6, 2026(3mo) | $25M |
| PREZISTAN021976 | 1 | Jun 26, 2027(12mo) | $25M |
| TOVIAZN022030 | 3 | Dec 7, 2027(1.4yr) | $21M |
| TROKENDI XRN201635 | 10 | Apr 4, 2028(1.7yr) | $18M |
| DALVANCEN021883 | 1 | May 23, 2028(1.9yr) | $18M |
| AFINITORN022334 | 2 | Jul 1, 2028(2.0yr) | $18M |
| RAYOSN202020 | 2 | Jan 7, 2028(1.5yr) | $16M |
| SIGNIFOR LAR KITN203255 | 3 | May 23, 2028(1.9yr) | $10M |
| OSPHENAN203505 | 2 | Jul 9, 2028(2.0yr) | $8M |
| ABILIFYN021436 | 2 | Mar 2, 2027(8mo) | $7M |
| SAVAYSAN206316 | 2 | Mar 28, 2028(1.7yr) | $5M |
| STRIVERDI RESPIMATN203108 | 1 | Jan 19, 2027(6mo) | $5M |
| VYONDYS 53N211970 | 1 | Jun 28, 2028(2.0yr) | $4M |
| ZOLINZAN021991 | 3 | Mar 18, 2028(1.7yr) | $4M |
| ORACEAN050805 | 1 | Dec 19, 2027(1.4yr) | $3M |
| SIGNIFORN200677 | 1 | Dec 14, 2026(5mo) | $2M |
| NEVANACN021862 | 1 | Jan 31, 2027(7mo) | $2M |
| AVEEDN022219 | 2 | May 8, 2027(10mo) | $2M |
| VERSACLOZN203479 | 1 | May 1, 2028(1.8yr) | $1M |
| SENSIPARN021688 | 2 | Sep 22, 2026(2mo) | $1M |
| CANASAN021252 | 2 | Jun 6, 2028(1.9yr) | $1M |
| DUAVEEN022247 | 1 | Mar 10, 2027(8mo) | $948K |
| TEKTURNAN021985 | 1 | Aug 19, 2026(1mo) | $868K |
| OMNARISN022004 | 1 | Feb 1, 2028(1.5yr) | $858K |
| VENLAFAXINE BESYLATEN215429 | 1 | May 16, 2028(1.8yr) | $759K |
| FENTORAN021947 | 2 | Jun 15, 2028(1.9yr) | $661K |
| VELETRIN022260 | 2 | Mar 15, 2027(8mo) | $606K |
| DYMISTAN202236 | 1 | Aug 24, 2026(1mo) | $604K |
| VIBATIVN022110 | 1 | Jan 1, 2027(6mo) | $553K |
| DUEXISN022519 | 5 | Jul 18, 2026(0mo) | $368K |